Putu Mirah Wahyu Subagia Putri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Putu Mirah Wahyu Subagia Putri has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Agung Brahmanthya Nadine Kepakisan
Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia
1 shared publication - Christo Timothy Mamangdean
Clinical Clerkship Program, Faculty of Medicine Universitas Udayana, Prof. Dr. I.G.N.G. Ngoerah Central General Hospital Denpasar Bali Indonesia
1 shared publication - I Gede Krisna Arim Sadeva
Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia
1 shared publication - I Gede Wikania Wira Wiguna
Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia
1 shared publication - I Komang Raditya Putra Pratama
Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia
1 shared publication - Kadek Meryndha Kumala Tungga
Faculty of Medicine, Udayana University, Denpasar, 80232, Indonesia, Indonesia
1 shared publication
Latest Publications
- Open Access
- 14 July 2026
- Published by Jurusan Analis Kesehatan Poltekkes Kemenkes Denpasar in Meditory : The Journal of Medical Laboratory
- Vol. 14 (1) , 156-177
EFFICACY AND SAFETY OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELL (CAR-T) THERAPY IN LYMPHOMA: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS
Background: Lymphoma (Hodgkin and non-Hodgkin) is a malignancy of the lymphatic system, with global prevalence reaching 2.8% and mortality rates reaching 248,700 cases each year. Therefore, Chimeric Antigen Receptor-Modified T cell therapy (CAR-T) was developed as a new approach to improve survival rates in lymphoma patients. Objective: This study aimed to evaluate the efficacy and safety of CAR-T cell therapy in lymphoma. Methods: PRISMA 2020 was used in the literature search and systematic review with the keywords "CAR-T Cell Therapy" and "Lymphoma". All statistical analyses were performed with R statistical software version 3.3 and MedCalc software version 22. A p-value ≤ 0.05 was considered statistically significant. Results: There were 16 studies involving 440 patients with lymphoma. The complete response rate was 62% (95% CI 55%-65%, I² = 40%). Meanwhile, cytokine release syndrome (CRS) occurred in 73% of cases (95% CI 49%-88%, I² = 80%). The overall Immune effector cell-associated neurotoxicity syndrome (ICANS) rate was 17% (95% CI 9%-30%, I² = 66%). There is no significant publication bias in all analyses (p-value>0.05). However, these results need to be interpreted with caution, considering the high heterogeneity in the pooled analysis results (I² > 50%).
- 14 July 2026
- Published by Jurusan Analis Kesehatan Poltekkes Kemenkes Denpasar in Meditory : The Journal of Medical Laboratory
- Vol. 14 (1) , 156-177
Open AccessEFFICACY AND SAFETY OF CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELL (CAR-T) THERAPY IN LYMPHOMA: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS
Background: Lymphoma (Hodgkin and non-Hodgkin) is a malignancy of the lymphatic system, with global prevalence reaching 2.8% and mortality rates reaching 248,700 cases each year. Therefore, Chimeric Antigen Receptor-Modified T cell therapy (CAR-T) was developed as a new approach to improve survival rates in lymphoma patients. Objective: This study aimed to evaluate the efficacy and safety of CAR-T cell therapy in lymphoma. Methods: PRISMA 2020 was used in the literature search and systematic review with the keywords "CAR-T Cell Therapy" and "Lymphoma". All statistical analyses were performed with R statistical software version 3.3 and MedCalc software version 22. A p-value ≤ 0.05 was considered statistically significant. Results: There were 16 studies involving 440 patients with lymphoma. The complete response rate was 62% (95% CI 55%-65%, I² = 40%). Meanwhile, cytokine release syndrome (CRS) occurred in 73% of cases (95% CI 49%-88%, I² = 80%). The overall Immune effector cell-associated neurotoxicity syndrome (ICANS) rate was 17% (95% CI 9%-30%, I² = 66%). There is no significant publication bias in all analyses (p-value>0.05). However, these results need to be interpreted with caution, considering the high heterogeneity in the pooled analysis results (I² > 50%).